VCP
TAK icon

Verus Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

Verus Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$5K Hold
327
– – ﹤0.01% 1198
2019
Q4 		$6K Buy
+327
New +$6.26K ﹤0.01% 1277

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verus Capital Partners's TAK Position: Q1 2020 in Review

Verus Capital Partners held its Takeda Pharmaceutical (TAK) position steady in Q1 2020 at 327 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1198.

Verus Capital Partners first reported a position in TAK in Q4 2019 and has held it in 2 quarters since. The position peaked at $6K in Q4 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2020.

  • Verus Capital Partners held 327 shares of Takeda Pharmaceutical worth $5K as of Q1 2020.
  • Verus Capital Partners left its Takeda Pharmaceutical share count unchanged in Q1 2020.
  • Takeda Pharmaceutical made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1198 holding.
  • Verus Capital Partners first reported a position in Takeda Pharmaceutical in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Takeda Pharmaceutical position peaked at $6K in Q4 2019.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.